The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). II. Characterization of CFS patients with special reference to their response to a new vitamin C infusion treatment. — CFSMEATLAS
The value of the dehydroepiandrosterone-annexed vitamin C infusion treatment in the clinical control of chronic fatigue syndrome (CFS). II. Characterization of CFS patients with special reference to their response to a new vitamin C infusion treatment.
Kodama, M, Kodama, T, Murakami, M · In vivo (Athens, Greece) · 1996
Quick Summary
This 1996 study examined whether high-dose vitamin C infusions, with or without a hormone called DHEA added, could help treat ME/CFS. Researchers treated 313 patients with chronic pneumonia-like illness that matched ME/CFS symptoms, often combined with antibiotics. The authors found that the combination of two types of vitamin C infusions worked better than one type alone, suggesting that low levels of certain body hormones might play a role in ME/CFS.
Why It Matters
This early study hypothesizes that deficiencies in endogenous glucocorticoids and androgens may contribute to ME/CFS pathogenesis, an area deserving continued research. The observation that hormone-modulating approaches may provide symptomatic benefit warrants investigation in contemporary, well-controlled trials with standardized ME/CFS diagnostic criteria.
Observed Findings
313 patients with chronic pneumonia-like illness met clinical criteria for CFS and showed female predominance (207F:106M), with median illness duration exceeding one month and incomplete recovery.
Combined vitamin C infusions (old + new DHEA-annexed formulation) appeared more effective than single-agent vitamin C for disease control.
Patients required long-term antibiotic use (erythromycin and chloramphenicol) alongside vitamin C infusions for symptom management.
Sole use of DHEA-annexed vitamin C infusions was associated with signs of gonadal steroid excess and other adverse effects.
Chronically ill pneumonia patients required prolonged medical care (>1 month) with recurrent exacerbations, distinguishing them from acute cold patients.
Inferred Conclusions
Deficient endogenous glucocorticoid and androgen activity may be involved in ME/CFS genesis and progression.
Balanced use of glucocorticoid-inducing and hormone-modulating vitamin C infusions may be necessary for optimal ME/CFS management.
ME/CFS may represent a distinct clinical entity separable from autoimmune/allergic disease and acute infection based on treatment response patterns.
Remaining Questions
What are the objective biochemical markers of glucocorticoid and androgen deficiency in ME/CFS patients, and do they correlate with symptom severity or treatment response?
What This Study Does Not Prove
This study does not establish causation between hormone deficiency and ME/CFS, nor does it prove that vitamin C or DHEA infusions are effective treatments—it reports only clinical observations without placebo controls or objective biomarker validation. The conflation of chronic pneumonia with ME/CFS criteria raises questions about diagnostic accuracy, and the role of antibiotics versus infusions cannot be separated. Findings cannot be generalized beyond the specific 1995 outbreak population studied.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Why did combined infusions outperform single-agent therapy—was this due to synergistic hormone restoration, vitamin C dose effects, or confounding from concurrent antibiotics?
Can these findings be replicated in modern cohorts using consensus diagnostic criteria (e.g., ICC 2011) and rigorous blinded, placebo-controlled designs?
What is the safety profile and long-term efficacy of DHEA-based interventions in ME/CFS, and are there subtypes of patients more likely to benefit?